{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhao SS"],"funding":["Versus Arthritis","British Society for Rheumatology","BSR Biologics Register in Rheumatoid Arthritis","National Institute for Health Research (NIHR)","NIHR Manchester Biomedical Research Centre"],"pagination":["4678-4686"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9707051"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["61(12)"],"pubmed_abstract":["<h4>Objectives</h4>Whether patients with RA benefit from repeated trials of biologic or targeted synthetic DMARDs (b/tsDMARDs) after three or more attempts is unknown. We aimed to describe treatment outcomes in each line of b/tsDMARD therapy.<h4>Methods</h4>Using data from the British Society for Rheumatology Biologics Register for RA from 2001 to 2020, change to a new b/tsDMARD (except biosimilar switches) was defined as a new line of therapy. Treatment outcomes were compared across lines of therapy, including DAS28 remission (≤2.6), low disease activity (LDA, ≤3.2) at 6 months and median time to drug discontinuation. Multiple imputation was used for missing data.<h4>Results</h4>A total of 22 934 individuals starting a first b/tsDMARD were included (mean age 56 years, 76% female), among w"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis."],"pmcid":["PMC9707051"],"funding_grant_id":["21755"],"pubmed_authors":["BSRBR-RA Contributors Group","Zhao SS","Bosworth A","Hyrich KL","Kearsley-Fleet L","Watson K"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis.","description":"<h4>Objectives</h4>Whether patients with RA benefit from repeated trials of biologic or targeted synthetic DMARDs (b/tsDMARDs) after three or more attempts is unknown. We aimed to describe treatment outcomes in each line of b/tsDMARD therapy.<h4>Methods</h4>Using data from the British Society for Rheumatology Biologics Register for RA from 2001 to 2020, change to a new b/tsDMARD (except biosimilar switches) was defined as a new line of therapy. Treatment outcomes were compared across lines of therapy, including DAS28 remission (≤2.6), low disease activity (LDA, ≤3.2) at 6 months and median time to drug discontinuation. Multiple imputation was used for missing data.<h4>Results</h4>A total of 22 934 individuals starting a first b/tsDMARD were included (mean age 56 years, 76% female), among w","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T09:43:10.089Z","creation":"2025-04-05T09:43:10.089Z"},"accession":"S-EPMC9707051","cross_references":{"pubmed":["35357421"],"doi":["10.1093/rheumatology/keac190"]}}